PiaSky Disease Interactions

The initiation of crovalimab (a complement inhibitor) is contraindicated in patients with unresolved serious Neisseria meningitidis infection. Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. The use of crovalimab increases susceptibility to serious meningococcal infections (meningococcemia and/or meningitis). Complete or update meningococcal vaccination at least 2 weeks prior to the first dose of crovalimab according to current guideline recommendations. If urgent therapy is indicated in a patient not up to date on meningococcal vaccination, provide antibacterial drug prophylaxis and vaccinate as soon as possible. Vaccination does not eliminate the risk of meningococcal infections. Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if an infection is suspected; infections may become rapidly life-threatening or fatal if not recognized and treated early. Consider treatment interruption in patients undergoing therapy for serious meningococcal infection.

Crovalimab has not been studied in patients with moderate to severe liver dysfunction. Mild liver dysfunction had no clinically significant effect on exposure to this drug.

Based on its mechanism of action, crovalimab may increase susceptibility to infections, especially with encapsulated bacteria, such as Neisseria species, but also with Streptococcus pneumoniae, Haemophilus influenzae, and to a lesser extent, Neisseria gonorrhoeae. Children treated with crovalimab may be at increased risk of developing serious infections due to Streptococcus pneumoniae and Haemophilus influenzae type b (Hib). Vaccination against S pneumoniae and Hib infections is recommended according to clinical guidelines. If crovalimab is administered to patients with active systemic infections, monitor closely for signs and symptoms of worsening infection; if infection worsens, consider treatment discontinuation.